ASPEN Trial: Difference between revisions
Jump to navigation
Jump to search
Rim Halaby (talk | contribs) (Created page with "__NOTOC__ {{LDL}} {{CMG}} '''Click here to download slides for ASPEN.''' ==Objective== ==References== {{Reflist|2}} {{Lipopedia}} Category:Lipopedia Category...") |
Rim Halaby (talk | contribs) |
||
Line 5: | Line 5: | ||
'''Click [[xxx|here]] to download slides for ASPEN.''' | '''Click [[xxx|here]] to download slides for ASPEN.''' | ||
== | ==Overview== | ||
In 1905 patients with diabetes and no prior CHD, the composite/primary end-point and secondary end-points of CV mortality, fatal/non-fatal MI, revascularizations, strokes or hospitalization for angina were similar in the treatment group (atorvastatin 10 mg daily) and placebo<ref name="pmid16801565">{{cite journal| author=Knopp RH, d'Emden M, Smilde JG, Pocock SJ| title=Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). | journal=Diabetes Care | year= 2006 | volume= 29 | issue= 7 | pages= 1478-85 | pmid=16801565 | doi=10.2337/dc05-2415 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16801565 }} [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17080974 Review in: ACP J Club. 2006 Nov-Dec;145(3):62] </ref>. | |||
==References== | ==References== |
Latest revision as of 04:15, 29 September 2014
Low Density Lipoprotein Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
ASPEN Trial On the Web |
American Roentgen Ray Society Images of ASPEN Trial |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Click here to download slides for ASPEN.
Overview
In 1905 patients with diabetes and no prior CHD, the composite/primary end-point and secondary end-points of CV mortality, fatal/non-fatal MI, revascularizations, strokes or hospitalization for angina were similar in the treatment group (atorvastatin 10 mg daily) and placebo[1].
References
- ↑ Knopp RH, d'Emden M, Smilde JG, Pocock SJ (2006). "Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN)". Diabetes Care. 29 (7): 1478–85. doi:10.2337/dc05-2415. PMID 16801565. Review in: ACP J Club. 2006 Nov-Dec;145(3):62